Liminatus Pharma enters SPAC merger deal with Iris Acquisition
Pharmaceutical Technology
DECEMBER 1, 2022
Liminatus Pharma has entered a definitive business combination agreement with special purpose acquisition company (SPAC) Iris Acquisition to create a business with a pro forma enterprise value of nearly $334m. These funds are expected to back the further business growth plan of Liminatus. Free Whitepaper.
Let's personalize your content